WO2012172336A3 - Treating inflammatory skin diseases - Google Patents

Treating inflammatory skin diseases Download PDF

Info

Publication number
WO2012172336A3
WO2012172336A3 PCT/GB2012/051345 GB2012051345W WO2012172336A3 WO 2012172336 A3 WO2012172336 A3 WO 2012172336A3 GB 2012051345 W GB2012051345 W GB 2012051345W WO 2012172336 A3 WO2012172336 A3 WO 2012172336A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemokine receptor
inflammatory skin
treating inflammatory
ccr9
cxcr1
Prior art date
Application number
PCT/GB2012/051345
Other languages
French (fr)
Other versions
WO2012172336A2 (en
Inventor
Graham Cotton
Ola Winqvist
Original Assignee
Ith Immune Therapy Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ith Immune Therapy Holdings filed Critical Ith Immune Therapy Holdings
Publication of WO2012172336A2 publication Critical patent/WO2012172336A2/en
Publication of WO2012172336A3 publication Critical patent/WO2012172336A3/en
Priority to US14/105,628 priority Critical patent/US9726666B2/en
Priority to US15/629,705 priority patent/US10429385B2/en
Priority to US15/629,713 priority patent/US10408832B2/en
Priority to US15/629,691 priority patent/US10451620B2/en
Priority to US15/629,708 priority patent/US10401357B2/en
Priority to US15/629,697 priority patent/US10502736B2/en
Priority to US15/629,700 priority patent/US10422800B2/en
Priority to US16/537,224 priority patent/US20190361020A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
    • B01J20/3206—Organic carriers, supports or substrates
    • B01J20/3208—Polymeric carriers, supports or substrates
    • B01J20/3212—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3268—Macromolecular compounds
    • B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
    • B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Anesthesiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A method for treating inflammatory skin disease comprises applying peripheral blood from a patient to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR4, CXCR1, CXCR2, CCR2, CCR6, CCR3, CCR5, CCR1, CCR9 or ChemR23 immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally CCR4, CXCR1, CXCR2, CCR2, CCR6, CCR3, CCR5, CCR1, CCR9 and ChemR23 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.
PCT/GB2012/051345 2011-06-13 2012-06-13 Treating inflammatory skin diseases WO2012172336A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US14/105,628 US9726666B2 (en) 2011-06-13 2013-12-13 Diagnosing and treating inflammatory diseases
US15/629,705 US10429385B2 (en) 2011-06-13 2017-06-21 Treating conditions associated with sepsis
US15/629,713 US10408832B2 (en) 2011-06-13 2017-06-21 Treating mental disorders
US15/629,691 US10451620B2 (en) 2011-06-13 2017-06-21 Treating conditions associated with metabolic syndrome
US15/629,708 US10401357B2 (en) 2011-06-13 2017-06-21 Treating cancer
US15/629,697 US10502736B2 (en) 2011-06-13 2017-06-21 Treating multiple sclerosis
US15/629,700 US10422800B2 (en) 2011-06-13 2017-06-21 Treating respiratory conditions
US16/537,224 US20190361020A1 (en) 2011-06-13 2019-08-09 Treating respiratory conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496228P 2011-06-13 2011-06-13
US61/496,228 2011-06-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/051352 Continuation-In-Part WO2012172342A2 (en) 2011-06-13 2012-06-13 Treating multiple sclerosis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2012/051355 Continuation-In-Part WO2012172345A2 (en) 2011-06-13 2012-06-13 Treating conditions associated with allergy
US14/105,628 Continuation-In-Part US9726666B2 (en) 2011-06-13 2013-12-13 Diagnosing and treating inflammatory diseases

Publications (2)

Publication Number Publication Date
WO2012172336A2 WO2012172336A2 (en) 2012-12-20
WO2012172336A3 true WO2012172336A3 (en) 2013-03-07

Family

ID=46317432

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/051345 WO2012172336A2 (en) 2011-06-13 2012-06-13 Treating inflammatory skin diseases

Country Status (1)

Country Link
WO (1) WO2012172336A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11730705B2 (en) 2019-05-02 2023-08-22 The Board Of Trustees Of The Leland Stanford Junior University Small molecule CMKLR1 antagonists in inflammatory disease
PE20221413A1 (en) * 2019-10-09 2022-09-20 Ose Immunotherapeutics HUMANIZED ANTIBODIES ANTI-CHEMOKINE-LIKE RECEPTOR 1 AND THEIR THERAPEUTIC APPLICATIONS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017979A1 (en) * 1999-03-11 2003-01-23 Matthias Mack Antibody and chemokine constructs and their use in the treatment of infections and immunological diseases
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
DE102005036505A1 (en) * 2004-07-30 2006-06-01 Adexter Gmbh Filtration process and assembly for removing harmful substances from human blood e.g. human immunodeficiency virus, Herpes virus, or plasmodia, comprises a reactor vessel of a biocompatible material
WO2007133147A1 (en) * 2006-05-12 2007-11-22 Ibd Column Therapies International Ab Method and means for treating inflammatory bowel disease
WO2010029317A2 (en) * 2008-09-10 2010-03-18 Ibd Column Therapies International Ab Treating inflammatory conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537362A (en) 1999-02-22 2002-11-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Biotinylated chemokine antibody conjugate
AU2009283199B2 (en) 2008-08-18 2015-08-13 Amgen Fremont Inc. Antibodies to CCR2

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017979A1 (en) * 1999-03-11 2003-01-23 Matthias Mack Antibody and chemokine constructs and their use in the treatment of infections and immunological diseases
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
DE102005036505A1 (en) * 2004-07-30 2006-06-01 Adexter Gmbh Filtration process and assembly for removing harmful substances from human blood e.g. human immunodeficiency virus, Herpes virus, or plasmodia, comprises a reactor vessel of a biocompatible material
WO2007133147A1 (en) * 2006-05-12 2007-11-22 Ibd Column Therapies International Ab Method and means for treating inflammatory bowel disease
WO2010029317A2 (en) * 2008-09-10 2010-03-18 Ibd Column Therapies International Ab Treating inflammatory conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ROTTMAN JAMES B ET AL: "Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris", LABORATORY INVESTIGATION, vol. 81, no. 3, March 2001 (2001-03-01), pages 335 - 347, XP002681949, ISSN: 0023-6837 *
TOMOMI NAKATANI ET AL: "CCR4+ memory CD4+ T lymphocytes are increased in peripheral blood and lesional skin from patients with atopic dermatitis", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 107, no. 2, 1 February 2001 (2001-02-01), pages 353 - 358, XP055035429, ISSN: 0091-6749, DOI: 10.1067/mai.2001.112601 *
Y. TERAKI ET AL: "Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris", CLINICAL AND EXPERIMENTAL DERMATOLOGY, vol. 29, no. 6, 1 November 2004 (2004-11-01), pages 658 - 663, XP055035428, ISSN: 0307-6938, DOI: 10.1111/j.1365-2230.2004.01638.x *

Also Published As

Publication number Publication date
WO2012172336A2 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
WO2012172341A3 (en) Treating cancer
PL398781A1 (en) Methods and kits for predicting the risk of reaction to infusion and lack of antibody-mediated responses by monitoring serum uric acid during therapy with pegylated uricase
WO2008070666A3 (en) Compositions and methods to treat cancer with cpg rich dna and cupredoxins
MY170570A (en) Human antibodies to the human glucagon receptor and methods of use thereof
EA200802086A1 (en) METHOD AND MEANS FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE INTESTINE
WO2010118035A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
EA201101568A1 (en) TREATMENT OF EX VIVO IMMUNOLOGICAL DISORDERS THROUGH PKC-TETA INHIBITORS
WO2009054873A3 (en) Anti-rantes antibodies and methods of use thereof
WO2010025321A3 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies
WO2011112732A3 (en) Methods of treating vascular inflammatory disorders
WO2014093051A3 (en) Cardiac stem cells and methods of identifying and using the same
MX2008015392A (en) Treatment of ischemic disease using erythropoietin.
WO2012172336A3 (en) Treating inflammatory skin diseases
NZ602474A (en) Regeneration of pancreatic islets and reversal of diabetes by islet transcription factor genes delivered in vivo
WO2010009129A3 (en) Methods of treating autoimmune diseases using cd4 antibodies
WO2012172346A3 (en) Treating respiratory conditions
WO2012172337A3 (en) Treating cardiovascular disease
WO2012172342A3 (en) Treating multiple sclerosis
WO2012172340A3 (en) Treating mental disorders
WO2012172343A3 (en) Treating primary sclerosing cholangitis
WO2012172344A3 (en) Treating conditions associated with sepsis
WO2012172345A3 (en) Treating conditions associated with allergy
WO2012172339A3 (en) Treating inflammatory arthritis
WO2007134147A3 (en) Method of vaccinating subjects receiving immune modulating therapy
Burnham et al. Roti Roti EC

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12727911

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12727911

Country of ref document: EP

Kind code of ref document: A2